Article Introduction (Source):
You may recall friends and family dumping buckets of ice on their head to raise funds for treating amyotrophic lateral sclerosis (ALS), a debilitating neuro-degenerative disease.
Current treatments are able to slow ALS’ progression but fail to maintain or restore motor movement. Now, multiple clinical trials conducted by an Israeli firm, Brainstorm Cell Therapeutics, show a first-ever reversal in expected decline for patients, likely to transform how we treat ALS.
“We showed a very strong improvement when we compare pre-treatment to post-treatment in the patients that were treated,” said Chaim Lebovits, CEO of Brainstorm, referring to the company’s advanced stem cell therapy treatment. “It means that it’s not even a slowdown of the disease, or a halt, but it’s a reversal of it. It’s unheard of in ALS, if we replicate this in a third trial.”
BrainStorm announced on Monday that its first patients had enrolled in a phase three clinical trial for its treatment of ALS at two American hospitals. The research will occur at Massachusetts General Hospital, UC Irvine Medical Center in California and the Mayo Clinic in Minnesota — and it will include some 200 patients, half of whom will be given a placebo.
Information and answers for those diagnosed with ALS, and those assisting someone with ALS.